BR9814426A - Novas composições farmacêuticas de trifosfato de uridina - Google Patents

Novas composições farmacêuticas de trifosfato de uridina

Info

Publication number
BR9814426A
BR9814426A BR9814426-0A BR9814426A BR9814426A BR 9814426 A BR9814426 A BR 9814426A BR 9814426 A BR9814426 A BR 9814426A BR 9814426 A BR9814426 A BR 9814426A
Authority
BR
Brazil
Prior art keywords
utp
formulation
pharmaceutical compositions
new
new pharmaceutical
Prior art date
Application number
BR9814426-0A
Other languages
English (en)
Inventor
Karol K Lacroix
Christy L Shaffer
Karla M Jacobus
Janet L Rideout
David J Drutz
Richard M Evans
William Pendergast
Original Assignee
Inspire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inspire Pharmaceuticals Inc filed Critical Inspire Pharmaceuticals Inc
Publication of BR9814426A publication Critical patent/BR9814426A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/10—Expectorants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"NOVAS COMPOSIçõES FARMACêUTICAS DE TRIFOSFATO DE URIDINA". São divulgadas novas composições farmacêuticas de 5'-trifosfato de uridina (UTP), para uso na promoção de depuração mucociliar aumentada de secreções mucosas retidas das vias aéreas, das orelhas médias/internas ou dos seios humanos. A nova Formulação (I) compreende o UTP e solução aquosa, tendo uma concentração terapêutica entre 5 e 45 mg/ml, uma tonicidade controlada dentro da faixa de 250 a 100 mOsM, um pH entre 7,0 e 7,5, e é estéril. A composição com o pH ajustado é capaz de armazenagem por um longo tempo, no estado refrigerado, com uma vida na prateleira de até 30 meses. A Formulação (I) pode ser liberada terapeuticamente em uma forma nebulizada ou em uma forma líquida. A nova Formulação (II) compreende o UTP em uma solução aquosa, tendo uma concentração terapêutica aproximando-se do limite de solubilidade do UTP, à temperatura ambiente, ou em uma suspensão que excede a solubilidade da droga. Esta alta concentração permite a liberação de uma quantidade terapêutica de UTP em volumes muito pequenos (50 a 100 <109>l) , adequados para a administração através de dispositivos segurados pelas mãos, portáteis, tais como os inaladores de doses medidas. A Formulação (II) tem vida na prateleira prolongada, sem a necessidade por refrigeração após ser liberada para o paciente.
BR9814426-0A 1997-12-23 1998-12-23 Novas composições farmacêuticas de trifosfato de uridina BR9814426A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/996,740 US5968913A (en) 1996-07-03 1997-12-23 Pharmaceutical compositions of uridine triphosphate
PCT/US1998/027409 WO1999032085A2 (en) 1997-12-23 1998-12-23 Novel pharmaceutical compositions of uridine triphosphate

Publications (1)

Publication Number Publication Date
BR9814426A true BR9814426A (pt) 2001-10-23

Family

ID=25543248

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9814426-0A BR9814426A (pt) 1997-12-23 1998-12-23 Novas composições farmacêuticas de trifosfato de uridina

Country Status (17)

Country Link
US (1) US5968913A (pt)
EP (1) EP1041969B1 (pt)
JP (1) JP2001526208A (pt)
KR (1) KR20010033310A (pt)
CN (1) CN1143672C (pt)
AR (1) AR014176A1 (pt)
AT (1) ATE235225T1 (pt)
AU (1) AU747350B2 (pt)
BR (1) BR9814426A (pt)
CA (1) CA2316018A1 (pt)
DE (1) DE69812708T2 (pt)
ID (1) ID26137A (pt)
IL (1) IL136895A0 (pt)
NO (1) NO20003246L (pt)
NZ (1) NZ505821A (pt)
WO (1) WO1999032085A2 (pt)
ZA (1) ZA9811833B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319908B1 (en) 1996-07-03 2001-11-20 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5′-tetraphosphate) and salts thereof
US5763447C1 (en) 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6872710B2 (en) * 1997-07-25 2005-03-29 Inspire Pharmaceuticals, Inc. Di(uridine 5′)-tetraphosphate and salts thereof
TW593331B (en) 1997-07-25 2004-06-21 Inspire Pharmaceuticals Inc Method for large-scale production of di(uridine 5')-tetraphosphate and salts thereof
CA2295515C (en) 1997-07-25 2006-03-14 Inspire Pharmaceuticals, Inc. Method for large-scale production of di(uridine 5'-tetraphosphate) and salts thereof
US7452870B2 (en) * 2000-08-21 2008-11-18 Inspire Pharmaceuticals, Inc. Drug-eluting stents coated with P2Y12 receptor antagonist compound
US7132408B2 (en) 2000-08-21 2006-11-07 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US7018985B1 (en) 2000-08-21 2006-03-28 Inspire Pharmaceuticals, Inc. Composition and method for inhibiting platelet aggregation
US6327215B1 (en) * 2000-09-28 2001-12-04 Vanguard International Semiconductor Corporation Local bit switch decode circuit and method
WO2003000056A1 (en) 2001-06-25 2003-01-03 Inspire Pharmaceuticals, Inc. Joint lubrication with p2y purinergic receptor agonists
MXPA04004215A (es) * 2001-11-06 2004-07-08 Inspire Pharmaceuticals Inc Metodo para el tratamiento o la prevencion de enfermedades inflamatorias.
MXPA05004121A (es) * 2002-10-18 2006-02-17 Molichem Medicines Inc Metodos para tratar la enfermedad de ojo reseco con lantibioticos.
CA2565545A1 (en) * 2004-05-06 2005-12-08 Molichem Medicines, Inc. Treatment of ocular diseases and disorders using lantibiotic compositions
WO2005107787A1 (en) * 2004-05-06 2005-11-17 Molichem Medicines, Inc. Treatment of membrane-associated diseases and disorders using lantibiotic containing compositions
US7368439B2 (en) * 2005-06-15 2008-05-06 Bar - Ilan University Dinucleoside poly(borano)phosphate derivatives and uses thereof
US20120077778A1 (en) * 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
EP2556832B1 (en) 2011-08-12 2017-07-19 Universitätsklinikum Freiburg Uridine and uridine analogues for use in the treatment of chronic obstructive pulmonary disease
US9034442B2 (en) * 2012-11-30 2015-05-19 Corning Incorporated Strengthened borosilicate glass containers with improved damage tolerance
US10117806B2 (en) * 2012-11-30 2018-11-06 Corning Incorporated Strengthened glass containers resistant to delamination and damage

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB916309A (en) * 1959-12-14 1963-01-23 Ile Auguil Soc Civ Improvements in and relating to new therapeutic preparation for use as a muscular and nervous stimulant
JPS60126220A (ja) * 1983-12-09 1985-07-05 Otsuka Pharmaceut Factory Inc 核酸成分組成物
GB9027968D0 (en) * 1990-12-22 1991-02-13 Fisons Plc Method of treatment
US5164740A (en) * 1991-04-24 1992-11-17 Yehuda Ivri High frequency printing mechanism
FR2677250B1 (fr) * 1991-06-05 1995-01-20 Synthelabo Compositions pharmaceutiques contenant de l'adenosine-5-triphosphate disodique.
EP0517573A1 (fr) * 1991-06-05 1992-12-09 Synthelabo Compositions pharmaceutiques pour le traitement des affections des voies respiratoires
US5292498A (en) * 1991-06-19 1994-03-08 The University Of North Carolina At Chapel Hill Method of treating lung disease with uridine triphosphates
EP0615470B1 (en) * 1991-12-04 1995-12-13 The Technology Partnership Public Limited Company Fluid droplet production apparatus and method
US5547131A (en) * 1992-12-04 1996-08-20 Bespak Plc Dispensing device with spray nozzle and driven piston
US5497763A (en) * 1993-05-21 1996-03-12 Aradigm Corporation Disposable package for intrapulmonary delivery of aerosolized formulations
US5593824A (en) * 1994-09-02 1997-01-14 Pharmacia Biotech, Inc. Biological reagent spheres
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US6423694B1 (en) * 1996-02-21 2002-07-23 Inspire Pharmaceuticals, Inc. Method of treating otitis media with uridine triphosphates and related compounds
NZ332426A (en) * 1996-03-27 2000-09-29 Univ North Carolina Method of treating diseases involving dysfunction of ciliary movement such as ciliary dyskinesia and infertility with uridine triphosphates (UTP) and related compounds
US5789391A (en) * 1996-07-03 1998-08-04 Inspire Pharmaceuticals, Inc. Method of treating sinusitis with uridine triphosphates and related compounds
US5962432A (en) * 1996-07-03 1999-10-05 Inspire Pharmaceuticals, Inc. Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
US5763447C1 (en) * 1996-07-23 2002-05-07 Inspire Pharmaceuticals Method of preventing or treating pneumonia in immobilized patients with uridine triphosphates and related compounds
US6159952A (en) * 1996-11-07 2000-12-12 Inspire Pharmaceuticals, Inc. Method of treating bronchitis with uridine triphosphate and related compounds

Also Published As

Publication number Publication date
JP2001526208A (ja) 2001-12-18
CN1284861A (zh) 2001-02-21
ID26137A (id) 2000-11-23
NO20003246D0 (no) 2000-06-21
WO1999032085A2 (en) 1999-07-01
EP1041969B1 (en) 2003-03-26
DE69812708D1 (de) 2003-04-30
EP1041969A2 (en) 2000-10-11
AR014176A1 (es) 2001-02-07
ZA9811833B (en) 1999-07-20
AU747350B2 (en) 2002-05-16
AU2092299A (en) 1999-07-12
CA2316018A1 (en) 1999-07-01
IL136895A0 (en) 2001-06-14
NO20003246L (no) 2000-08-23
CN1143672C (zh) 2004-03-31
DE69812708T2 (de) 2004-01-29
ATE235225T1 (de) 2003-04-15
NZ505821A (en) 2002-09-27
KR20010033310A (ko) 2001-04-25
WO1999032085A3 (en) 1999-09-02
US5968913A (en) 1999-10-19

Similar Documents

Publication Publication Date Title
WO1999032085A3 (en) Novel pharmaceutical compositions of uridine triphosphate
ES2836184T3 (es) Formulaciones tópicas de co-enzima Q10 y tratamiento de heridas
AU4408997A (en) Method of treating sinusitis with uridine triphosphates and related compounds
BR9906372A (pt) Composição farmaceutica aquosa para aplicação na mucosa
BR112018000592B1 (pt) Composição de desbloqueio de nariz congestionado tendo atividade antiviral
BR9914384A (pt) Dispositivo e método para liberação de um agente ativo em aerossol aos pulmões de um paciente humano
ES2284714T3 (es) Uso de derivados de acido hialuronico para la inhibicion de artritis inflamarortias.
BR0214757A (pt) Formulações farmacêuticas de derivados de platina
BR0109672A (pt) Uso de zd6126 ou de um seu sal farmaceuticamente aceitável e um de: um agente antitumoral de plantina e um taxano, composição farmacêutica, produto de combinação, kit, e, método para a produção de um efeito de danificação vascular em um animal de sangue quente
US20240033490A1 (en) Nitric oxide-releasing device
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
US7056889B2 (en) Compounds that bind P2Y2 or P2Y1 receptors
BR0309057A (pt) Formulações lìquidas com baixa dosagem em entecavir e uso
ATE350024T1 (de) Flüssige zubereitung enthaltend tobramycin
Fulkerson et al. In vitro hexosamine depletion of intact articular cartilage by e‐prostaglandins
PT92188B (pt) Processo para a preparacao de uma solucao aquosa contendo acido cromoglicico e salbutamol
US5962432A (en) Sterilized, isotonic and pH-adjusted pharmaceutical formulation of uridine triphosphate
BR0207866A (pt) Uso de flumazenil na preparação de um medicamento para o tratamento da dependência de cocaìna
AR008559A1 (es) Uso de pentosanpolisulfato (pps) o de una sal farmaceuticamente aceptable del mismo
KR900013935A (ko) 대머리 환자의 발모촉진용 약제학적 조성물의 제조에 있어서 5&#39;-데옥시-5&#39;-메틸티오아데노신, s-아데노실메티오닌 및 이들 염의 용도 및 약제학적 조성물
BR0212744A (pt) Formulações de cisplatina de toxicidade reduzida e métodos para uso das mesmas
RU2008110933A (ru) Применение амброксола для лечения риновирусных инфекций
CN116437903A (zh) 肝素组合物在通过吸入途径通过软雾吸入器或振动网状技术雾化器治疗病毒性肺病、急性和/或慢性肺病中的用途
BRPI0506710A (pt) composições farmacêuticas de liberação controlada
ES2336578T3 (es) Uso de pilocarpina para el tratamiento de hiposialismos.

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1910 DE 14/08/2007.